Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

• Revenue in USD (TTM)5.05m
• Net income in USD-46.90m
• Incorporated1989
• Employees60.00

• Location
  Armata Pharmaceuticals Inc5005 Mcconnell AveLOS ANGELES 90066United StatesUSA
• Phone+1 (310) 665-2928
• Fax+1 (310) 665-2963
• Websitehttps://www.armatapharma.com/